Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 583

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 583
---
”, and together with BDSI, the “Sellers”) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the “ELYXYB Territory”). As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr. Reddy’s Laboratories Limited, a company incorporated under the laws of India (“DRL”), dated August 3, 2021 (the “DRL APA”), including an irrevocable, royalty-free, exclusive license to know-howand patents of DRL related to ELYXYB that is necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. F-72 As of each of September 30, 2025 and December 31, 2024, the Company had ending balances of accrued royalty payables of $ 0.1 million. During the three and nine months ended September 30, 2025, the Company made royalty payments in the amount of $ 0.1 million and $ 0.2million, respectively. The Company made royalty payments in the amount of $ 0.1million during each of the three and nine months ended September 30, 2024. As of September 30, 2025, a regulatory milestone payment of $ 1.0million had been accrued. ZTlido Rest of World License Agreement On February 22, 2025 (the “Lido Effective Date”), Scilex Pharma entered into a License Agreement (the “ Lido License Agreement”) with RoyaltyVest Ltd. (the “Licensee”) with respect to services, compositions, products, dosages and formulations comprising lidocaine that have been or are later developed by or on behalf of Scilex Pharma, including the product and any future product defined as a “Product” under Scilex Pharma’s existing (i) Product Development Agreement, dated as of May 11, 2011, with